Management and board

Management and board

 

Mats Rönngard 

CEO/BOARD MEMBER

Born 1956. Grew up in an entrepreneurial family and studied economics at Lund University. Mats is an entrepreneur with more than 30 years of experience in helping numerous international listed companies, primarily in fast-moving consumer products and pharmaceuticals, with their marketing and sales. His list of customers include companies such as Swedish Match, Carlsberg, Kraft Foods, AstraZeneca, and Novo Nordisk.

Contact Mats

 

Annette Agerskov 

DEPUTY MANAGING DIRECTOR

Born 1960. Solid work experience with nicotine substitutes in general and with nicotine gum in particular. For most of her career, Annette has held senior positions in Fertin Pharma A/S, one of the world's largest nicotine gum manufacturers. Annette's many years in the nicotine substitute industry has generated a broad network of contacts with both suppliers and retailers. Annette has a Master's Degree in Marketing and International Business from Aarhus Business School.

Contact Annette


 

Anders Ermén

Board Chairman 

Born 1963. Own business since 1996, specialising in accounting, business development, and management. Anders has over 20 years of experience in the music and media industry, both nationally and internationally, as well as experience in the pharmaceutical industry. Anders also has extensive experience in tax issues and contract negotiations.

 

Tomas Eriksson

BOARD MEMBER

Born 1964. Co-founder and CEO of A1 M Pharma, a drug development company that focuses on pre-eclampsia and acute kidney damage. Tomas has a Bachelor of Science degree from Lund University with a main focus of business economics. Tomas has vast experience of working in senior positions in medical technology and diagnostics, such as: Area Manager Gambro AB, Sales Manager Nordic Bioscience (Denmark) and Sales & Marketing Director in Magle Life Science AB.

 

Mats Persson

BOARD MEMBER

Born 1961. CEO of Hamlet Pharma, which is a company that conducts drug development with an aim of developing new cancer treatment drugs. Over several years, Mats has held senior positions at companies such as LEO Pharma in Denmark, where Mats was part of the research and development management team. Mats has a PhD in biochemistry and has more than 20 years of experience in clinical research and development from AstraZeneca.

Anders Jungbeck 

BOARD MEMBER